266 related articles for article (PubMed ID: 22475042)
1. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.
Kim Le T; Winfree KB; Yang H; Marynchenko M; Yu AP; Frois C; Wu EQ
J Med Econ; 2012; 15(4):786-95. PubMed ID: 22475042
[TBL] [Abstract][Full Text] [Related]
2. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
4. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
Lang K; Sussman M; Friedman M; Su J; Kan HJ; Mauro D; Tafesse E; Menzin J
Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):582-8. PubMed ID: 19528407
[TBL] [Abstract][Full Text] [Related]
5. Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database.
Fisher MD; Fernandes AW; Olufade TO; Miller PJ; Walker MS; Fenton M
Clin Ther; 2018 Apr; 40(4):562-573. PubMed ID: 29530457
[TBL] [Abstract][Full Text] [Related]
6. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.
Ray S; Bonthapally V; Holen KD; Gauthier G; Wu EQ; Cloutier M; Guérin A
J Med Econ; 2013; 16(2):221-30. PubMed ID: 23153319
[TBL] [Abstract][Full Text] [Related]
8. Burden of venous leg ulcers in the United States.
Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
[TBL] [Abstract][Full Text] [Related]
9. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
12. Antiepileptic drug treatment patterns and economic burden of commercially-insured patients with refractory epilepsy with partial onset seizures in the United States.
Chen SY; Wu N; Boulanger L; Sacco P
J Med Econ; 2013; 16(2):240-8. PubMed ID: 23171361
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.
Lafuma A; Cotté FE; Le Tourneau C; Emery C; Gaudin AF; Torreton E; Gourmelen J; Bonastre J
J Med Econ; 2019 Jul; 22(7):698-705. PubMed ID: 30895832
[No Abstract] [Full Text] [Related]
14. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL
Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883
[TBL] [Abstract][Full Text] [Related]
15. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
16. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data.
Lang K; Menzin J; Earle CC; Jacobson J; Hsu MA
Arch Otolaryngol Head Neck Surg; 2004 Nov; 130(11):1269-75. PubMed ID: 15545580
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
18. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
19. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
